DelveInsight’s, “HER2 Positive Gastric Cancer Pipeline Insight” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in HER2 Positive Gastric Cancer pipeline landscape. It covers the HER2 Positive Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Gastric Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n\nExplore our latest breakthroughs in HER2 Positive Gastric Cancer Research. Learn more about our innovative pipeline today! @ <a>HER2 Positive Gastric Cancer Pipeline Outlook</a>\n\nKey Takeaways from the HER2 Positive Gastric Cancer Pipeline Report\n\nIn July 2025, AstraZeneca announced a study is to assess the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.\n\nIn July 2025, Daiichi Sankyo conducted a clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS\n\nDelveInsight’s HER2 Positive Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2 Positive Gastric Cancer treatment. The leading HER2 Positive Gastric Cancer Companies such as Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.\n\nPromising HER2 Positive Gastric Cancer Therapies such as YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.\n\nStay informed about the cutting-edge advancements in HER2 Positive Gastric Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ <a>HER2 Positive Gastric Cancer Clinical Trials Assessment</a>\n\nHER2 Positive Gastric Cancer Emerging Drugs\n\nSHR-A1811: Jiangsu HengRui Medicine Co., Ltd.\n\nSHR-A1811 is a novel anti-HER2 antibody-drug conjugate (ADC) that features an optimized molecular design to enhance plasma stability and bystander effect. Hengrui Pharma is currently conducting more than 10 clinical studies of SHR-A1811 from phase 1 to phase 3 to evaluate its safety and efficacy as single agent or combination therapy in a wide variety of cancer indications. Currently, the drug is in Phase III stage of its development for the treatment of HER2-positive Gastric Cancer.\n\nCinrebafusp alfa: Pieris Pharmaceuticals\n\nCinrebafusp alfa (PRS-343) is a 4-1BB/HER2 fusion protein comprising 4-1BB-targeting Anticalin proteins and a HER2-targeting antibody. The drug candidate is currently in phase 2 development for the treatment of HER2-expressing solid tumors. In phase 1 studies, cinrebafusp alfa has shown an acceptable safety profile at all doses tested with no dose-limiting toxicities. The bispecific also showed a dose response and a 4-1BB-driven mechanism of action based on clinical benefit and pharmacodynamic correlates. Currently, the drug is in Phase II stage of its development for the treatment of HER2-positive Gastric Cancer.\n\nBI-1607: BioInvent International\n\nBI-1607 is an FcγRIIB-blocking antibody that differs from BI-1206 (BioInvent’s clinical-stage FcγRIIB antibody) in that it has been engineered for reduced Fc-binding to FcγRs. Preclinical proof-of-concept data indicate that combined treatment with BI-1607 may both enhance efficacy of current anti-HER2 regimens and increase response rates in patients no longer responding to anti-HER2-directed therapies such as trastuzumab. Currently, the drug is in Phase I/II stage of its development for the treatment of HER2-positive Gastric Cancer.\n\nThe HER2 Positive Gastric Cancer pipeline report provides insights into\n\nThe report provides detailed insights about companies that are developing therapies for the treatment of HER2 Positive Gastric Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Positive Gastric Cancer Treatment. HER2 Positive Gastric Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. HER2 Positive Gastric Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Positive Gastric Cancer market.\n\nLearn more about HER2 Positive Gastric Cancer Drugs opportunities in our groundbreaking HER2 Positive Gastric Cancer Research and development projects @ <a>HER2 Positive Gastric Cancer Unmet Needs</a>\n\nHER2 Positive Gastric Cancer Companies\n\nJiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.\n\nHER2 Positive Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration\n\nOral\nIntravenous\nSubcutaneous\nParenteral\nTopical\n\nHER2 Positive Gastric Cancer Products have been categorized under various Molecule types such as\n\nRecombinant fusion proteins\nSmall molecule\nMonoclonal antibody\nPeptide\nPolymer\nGene therapy\n\nDiscover the latest advancements in HER2 Positive Gastric Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ <a>HER2 Positive Gastric Cancer Market Drivers and Barriers, and Future Perspectives</a>\n\nHER2 Positive Gastric Cancer Companies and Therapies\n\nBDC-1001: Bolt Therapeutics Inc.\nKN026: Shanghai JMT-Bio Inc.\nYH32367: Yuhan Corporation\nMargetuximab: MacroGenics\nZanidatamab: Jazz Pharmaceuticals\n\nScope of the HER2 Positive Gastric Cancer Pipeline Report\n\nCoverage- Global\nHER2 Positive Gastric Cancer Companies- Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.\nHER2 Positive Gastric Cancer Therapies- YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.\nHER2 Positive Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination\nHER2 Positive Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III\n\nFor a detailed overview of our latest research findings and future plans, read the full details of HER2 Positive Gastric Cancer Pipeline on our website @ <a>HER2 Positive Gastric Cancer Drugs and Companies</a>\n\nTable of Content\n\nIntroduction\nExecutive Summary\nHER2-positive Gastric Cancer: Overview\nPipeline Therapeutics\nTherapeutic Assessment\nHER2-positive Gastric Cancer– DelveInsight’s Analytical Perspective\nLate Stage Products (Phase III)\nSHR-A1811: Jiangsu HengRui Medicine Co., Ltd.\nDrug profiles in the detailed report…..\nMid Stage Products (Phase II)\nCinrebafusp alfa: Pieris Pharmaceuticals\nDrug profiles in the detailed report…..\nEarly Stage Products (Phase I/II)\nBI-1607: BioInvent International\nDrug profiles in the detailed report…..\nPreclinical and Discovery Stage Products\nDrug Name: Company Name\nDrug profiles in the detailed report…..\nInactive Products\nHER2-positive Gastric Cancer Key Companies\nHER2-positive Gastric Cancer Key Products\nHER2-positive Gastric Cancer- Unmet Needs\nHER2-positive Gastric Cancer- Market Drivers and Barriers\nHER2-positive Gastric Cancer- Future Perspectives and Conclusion\nHER2-positive Gastric Cancer Analyst Views\nHER2-positive Gastric Cancer Key Companies\nAppendix\n\nAbout Us\n\nDelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

HER2+ Gastric Cancer Pipeline Appears Promising With 20+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

DelveInsight's report highlights 20+ biotech and pharmaceutical companies developing HER2-positive gastric cancer therapies, including clinical trials for drugs like rilvegostomig, trastuzumab deruxtecan, and SHR-A1811. The report covers pipeline drugs across phases I-III, therapeutic mechanisms, and collaborations in oncology research.